In the latest trading session, 0.57 million Trevi Therapeutics Inc (NASDAQ:TRVI) shares changed hands as the company’s beta touched 0.99. With the company’s most recent per share price at $3.27 changing hands around $0.15 or 4.81% at last look, the market valuation stands at $237.37M. TRVI’s current price is a discount, trading about -22.32% off its 52-week high of $4.00. The share price had its 52-week low at $0.97, which suggests the last value was 70.34% up since then. When we look at Trevi Therapeutics Inc’s average trading volume, we note the 10-day average is 0.27 million shares, with the 3-month average coming to 273.51K.
Analysts gave the Trevi Therapeutics Inc (TRVI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.10. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended TRVI as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Trevi Therapeutics Inc’s EPS for the current quarter is expected to be -0.12.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Trevi Therapeutics Inc (NASDAQ:TRVI) trade information
Instantly TRVI is in green as seen in intraday trades today. With action 2.83%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 144.03%, with the 5-day performance at 2.83% in the green. However, in the 30-day time frame, Trevi Therapeutics Inc (NASDAQ:TRVI) is -4.94% down. Looking at the short shares, we see there were 1.51 million shares sold at short interest cover period of 3.46 days.
The consensus price target for the stock as assigned by Wall Street analysts is 9, meaning bulls need an upside of 63.67% from its recent market value. According to analyst projections, TRVI’s forecast low is 6 with 12 as the target high. To hit the forecast high, the stock’s price needs a -266.97% plunge from its current level, while the stock would need to soar -83.49% for it to hit the projected low.
Trevi Therapeutics Inc (TRVI) estimates and forecasts
Data shows that the Trevi Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 11.22% over the past 6 months, a -62.07% in annual growth rate that is considerably lower than the industry average of 17.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 27.24%. The 2024 estimates are for Trevi Therapeutics Inc earnings to decrease by -60.64%.
TRVI Dividends
Trevi Therapeutics Inc is expected to release its next quarterly earnings report on 2024-Nov-07.
Trevi Therapeutics Inc (NASDAQ:TRVI)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.25% of Trevi Therapeutics Inc shares while 77.36% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 78.34%. There are 77.36% institutions holding the Trevi Therapeutics Inc stock share, with NEA MANAGEMENT COMPANY, LLC the top institutional holder. As of 2024-06-30, the company held 11.4255% of the shares, roughly 11.37 million TRVI shares worth $33.88 million.
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 7.4169% or 7.38 million shares worth $22.0 million as of 2024-06-30.
